Benefits of early initiation of Certican® after liver transplantation
Renal-sparing strategies as early as 1-month post-LT with everolimus-facilitated CNI reduction is explored and recommended to reduce CNI-associated toxicities.1
6.7% vs. 9.7%
Incidence of tBPAR, graft loss
or death at 12 months
(p<0.001 for noninferiority)2
11.5% vs. 14.6%
Incidence of tBPAR, graft loss
or death 3 years post LT
(p=0.334)3
8.50 mL/min/1.73m2
eGFR difference
at 12 months (97.5% CI 3.74, 13.27 mL min/1.73 m2, p<0.001 for superiority)2
Mean eGFR rate decline
3 years post LT (p=0.334)3
No or Low HCC recurrence in Certican® + rCNI vs. standard CNI
*p–value is not reported
Abbreviations:
IS, immunosuppressant; LT, liver transplant; CNI, Calcineurin inhibitors; tBPAR, treated biopsy-proven acute rejection; eGFR, estimated glomerular filtration rate; rCNI, reduced-exposure calcineurin inhibitor; HCC, hepatocellular carcinoma
References:
1. De Simone P, et al. Transplantation. 2017;101(2):239-251. 2. De Simone P, et al. Am J Transplant. 2012;12(11):3008-3020. 3. Fischer L, et al. Transplantation. 2015;99(7):1455-1462. 4. Lee et al. Transplantation. 2021;105(7):1564-1575. 5. Jeng LB, et al. Am J Transplant. 2018;18(6):143 -1446.
20 Pasir Panjang Road #10-25/28 Mapletree Business City (West Tower) Singapore 117439
Phone: +65 6722 6010
This content is not for local distribution. This should be modified to accommodate local guidance before local distribution.
FOR HEALTHCARE PROFESSIONALS ONLY
Please visit https://www.novartis.com/sg-en/product-list/certican to access or download the Package Insert.
Alternatively, please scan this code for more Information about this medicine.
FA-11484252_2027Aug05